News and Announcements
Skrilla Token (SKR) Now Transferrable
- Published December 08, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Skrilla Token (SKR) can now be traded.
- The token can be bought and sold through EtherDelta.
- Skrilla Bonus Token will be distributed in the coming days.
Trading SKR
It is now possible to buy and sell the Skrilla token through EtherDelta. We are in discussions with other exchanges and we are aiming to be listed on at least one additional exchange in the near future. As always we will keep you in the loop with our progress on this front.
Withdrawing tokens to your MyEtherWallet
In order to access your SKR tokens through MyEtherWallet you will need to carry out a simple procedure to withdraw them to your wallet. Follow this link for a step by step guide on how to do it. Fear not, it is easy! But should you need further assistance, don’t hesitate to get in touch via [email protected].
Bounty tokens
We will begin to distribute the bounty tokens in the coming days. If you participated in the bounty, make sure you have listed your contract address in the Bitcointalk thread, to ensure there is no delay in receiving your SKR.
Bonus tokens
Similar to the Bounty Tokens we will begin to distribute the 100SKR bonus tokens in the coming days. Please note, in order to be eligible for the 100SKR bonus tokens, you needed to have:
- Emailed us your contract address prior to the start of the Token Sale (November 6); and
- Purchased SKR tokens during the token sale
About Skrilla
Skrilla is a licensed, peer to peer (P2P) esports wagering marketplace. Skrilla recently launched a Daily Fantasy platform within Australia, with international rollout planned for 2018. Concurrently they have created the Skrilla token (SKR), the first step towards the platform operating solely on a decentralised blockchain, utilising a single global currency with which to bet across jurisdictions.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
